Isomorphic Labs Secures $600M to Revolutionize AI Drug Discovery
Deal News | Mar 31, 2025 | Business Cloud
Isomorphic Labs, a London-based startup led by DeepMind founder Sir Demis Hassabis, has successfully closed its first external funding round, raising $600 million. The round was led by Thrive Capital, with contributions from investors such as Google Ventures and Alphabet. Established in 2021, Isomorphic Labs aims to apply artificial intelligence to accelerate drug discovery and design, ultimately striving to provide treatments to patients worldwide. Prominent pharmaceutical companies such as Eli Lilly and Novartis are already counted among its clients. This substantial investment will further refine the company's AI-powered drug design engine and support its progression into clinical development. The funding is seen as a pivotal move towards Isomorphic Labs' mission of transforming the biotechnology landscape and potentially solving all diseases with AI-powered solutions.
Sectors
- MedTech
- Investment
- Pharmaceuticals
Geography
- United Kingdom – Isomorphic Labs is based in London, making the UK a relevant geography for the startup's activities and headquarters.
- United States – Thrive Capital, Google Ventures, and Alphabet, key investors in the funding round, are US-based entities, highlighting the international investment interest.
Industry
- MedTech – The article focuses on Isomorphic Labs, which specializes in AI-driven drug discovery - a cutting-edge segment of the MedTech industry.
- Investment – This article discusses a significant investment round involving prominent investors like Thrive Capital, Google Ventures, and Alphabet, emphasizing the financial aspects of the story.
- Pharmaceuticals – Isomorphic Labs collaborates with pharmaceutical companies like Eli Lilly and Novartis, indicating its active engagement in the pharmaceuticals sector.
Financials
- $600 million – The total amount raised by Isomorphic Labs in its first external financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Isomorphic Labs | Target Company | Company | A MedTech company using AI to accelerate drug discovery and design, founded by DeepMind's Sir Demis Hassabis. |
| Thrive Capital | Investor | Company | A leading investment firm that led the $600 million funding round for Isomorphic Labs. |
| Google Ventures | Investor | Company | A venture capital investment arm of Alphabet Inc., participating in the funding round. |
| Alphabet | Investor | Company | The parent company of Google, investing in Isomorphic Labs' AI drug discovery efforts. |
| Sir Demis Hassabis | Founder and Leader | Person | Founder of Isomorphic Labs and a key visionary in deploying AI for drug discovery and healthcare solutions. |
| Eli Lilly | Client | Company | A pharmaceutical giant and client of Isomorphic Labs, utilizing AI-driven solutions for drug discovery. |
| Novartis | Client | Company | A major pharmaceutical company that collaborates with Isomorphic Labs on advancing AI drug discovery. |